Sociedad Americana de Hirudoterapia

A comparison of the enzymatic properties of three recombinant isoforms of thrombolytic and antibacterial protein — destabilase-lysozyme from medicinal leech

Biochemical characterization published in BMC Biochemistry (2015)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Observational studyFarmacología salivalKurdyumov AS et al. · BMC biochemistry, 2015

Abstract

BACKGROUND: Destabilase-Lysozyme (mlDL) is a multifunctional i-type enzyme that has been found in the secretions from the salivary glands of medicinal leeches. mlDL has been shown to exhibit isopeptidase, muramidase and antibacterial activity. This enzyme attracts interest because it expresses thrombolytic activity through isopeptidolysis of the ε-(γ-Glu)-Lys bonds that cross-link polypeptide chains in stabilised fibrin. To date, three isoforms of mlDL have been identified. The enzymatic properties of pure mlDL isoforms have not yet been described because only destabilase complexes containing other proteins could be isolated from the salivary gland secretion and because low product yield from the generation of recombinant proteins has made comprehensive testing difficult. RESULTS: In the present study, we optimised the procedures related to the expression, isolation and purification of active mlDL isoforms (mlDL-Ds1, mlDL-Ds2, mlDL-Ds3) using an Escherichia coli expression system, and we detected and compared their muramidase, lytic, isopeptidase and antimicrobial activities. After optimisation, the product yield was 30 mg per litre of culture. The data obtained in our study led to the suggestion that the recombinant mlDL isoforms isolated from inclusion bodies form stable oligomeric complexes. Analyses of the tested activities revealed that all isoforms exhibited almost identical patterns of pH and ionic strength effects on the activities. We determined that mlDL-Ds1, 2, 3 possessed non-enzymatic antibacterial activity independent of their muramidase activity. For the first time, we demonstrated the fibrinolytic activity of the recombinant mlDL and showed that only intact proteins possessed this activity, suggesting their enzymatic nature. CONCLUSIONS: The recombinant Destabilase-Lysozyme isoforms obtained in our study may be considered potential thrombolytic agents that act through a mechanism different from that of common thrombolytics.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAnti-Bacterial AgentsBacillus subtilisChromatography, AffinityChromatography, GelCircular DichroismDrug StabilityEndopeptidasesEnzyme StabilityEscherichia coliFibrinolytic AgentsHirudo medicinalis

Resumen

Comparative enzymatic characterization of three recombinant destabilase-lysozyme isoforms from H. medicinalis. Isoforms differ in lysozyme activity but conserve isopeptidase function.

Por qué esto importa para la hirudoterapia

Esta investigación optimizó la expresión, el aislamiento y la purificación de tres isoformas recombinantes de la desestabilasa-lisozima (mlDL) de la sanguijuela medicinal mediante un sistema de E. coli, con el fin de comparar sus propiedades enzimáticas. El estudio confirmó que las tres isoformas poseen actividades muramidasa, antibacteriana y fibrinolítica, siendo esta última enzimática y dependiente de la estructura proteica intacta. Esto es relevante para ASH, ya que caracteriza de forma exhaustiva los perfiles funcionales específicos de distintos componentes del secretoma de la sanguijuela, reforzando su potencial como agentes trombolíticos y antibacterianos. Sin embargo, el alcance se limita estrictamente a la caracterización bioquímica in vitro, sin ofrecer validación in vivo ni clínica.

Citación

A comparison of the enzymatic properties of three recombinant isoforms of thrombolytic and antibacterial protein — destabilase-lysozyme from medicinal leech.

Kurdyumov AS et al. · BMC biochemistry, 2015

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.